表紙
市場調查報告書

免疫檢查點抑制劑全球市場:未來展望 (2022年)

Global Immune Checkpoint Inhibitors Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 606409
出版日期 內容資訊 英文 130 Pages
訂單完成後即時交付
價格
免疫檢查點抑制劑全球市場:未來展望 (2022年) Global Immune Checkpoint Inhibitors Market Outlook 2022
出版日期: 2020年03月01日內容資訊: 英文 130 Pages
簡介

免疫檢查點抑制劑在各種腫瘤免疫抑制劑中的開發是最尖端的,是一項具未來潛力的癌症免疫抑制方法。預估全球免疫檢查點抑制劑市場規模將於2022年超過250億美元。產品類別方面,預估PD-1將占最大占比。

本報告研究分析全球免疫檢查點抑制劑市場,彙整疾病和產品概要、主要市場推動和阻礙因素、市場整體趨勢展望,提供按產品等級、症狀的詳細動向,近期資本交易、業務合作動向、PIPELINE產品臨床試驗動向、主要企業簡介等情報。

第1章 分析師見解

第2章 研究方法

第3章 免疫檢查點抑制劑:概要

第4章 市場動態

  • 市場推動因素
    • 癌症發病率上升
    • 免疫檢查點抑制劑銷售推動市場成長
    • 老年人口的增加
    • 已開發國家的高醫療費用支出
    • 強健PIPELINE產品
    • 各種適應症中的效能提升
    • 癌症免疫產品的大量核准和大幅普及
  • 課題
    • 免疫療法後的副作用增加
    • 癌症免疫療法的高昂開發費用
    • 高昂治療費用
    • 缺乏認知
  • 市場機會
    • Opdivo和Keytruda帶來龐大成長機會
    • 合併療法:大幅提升生存率的可能性
    • 中小企業帶來的次世代免疫療法龐大市場機會

第5章 全球免疫檢查點抑制劑市場未來展望 (2022年)

第6章 全球免疫檢查點抑制劑銷售,按產品類別

  • CTLA-4 抑制劑
    • Yervoy (Ipilimumab)
  • PD-1 (Programmed Death 1)/PD-L1 (Programmed Death Ligand-1) 抑制劑
    • Tecentriq (Atezolizumab)
    • Bavencio (Avelumab)
    • Imfinzi (Durvalumab)
    • Opdivo (Nivolumab)
    • Keytruda (Pembrolizumab)

第7章 主要適應症中的免疫檢查點抑制劑應用

  • 頭部、頸部癌
  • 肺癌
  • 黑色素瘤
  • 淋巴瘤
  • 白血病
  • 其他

第8章 市場趨勢和發展

  • 盈利的投資趨勢
  • 標靶療法和合併療法的出現
  • NSCLC和黑色素瘤:對IO市場的龐大貢獻
  • Bristol-Myers Squibb和Merck & Co:免疫腫瘤學市場的頂尖交易商

第9章 免疫檢查點抑制劑市場之策略合作與聯盟

第10章 免疫檢查點抑制劑PIPELINE分析

第11章 主要企業分析

  • Genentech、Inc. (Roche Group成員)
  • CureTech Ltd.
  • NewLink Genetics Corporation
  • Novartis AG
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • AstraZeneca Plc
  • Pfizer Inc
  • Ono Pharmaceutical Co., Ltd.
  • EMD Serono, Inc.
目錄

Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients. Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.

According to the report "Global Immune Checkpoint Inhibitors Market Outlook", the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.

Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.

The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.

On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

TABLE OF CONTENTS

1. Analyst View

2. Research Methodology

3. Immune Checkpoint Inhibitors: Overview

4. Market Dynamics

  • 4.1 Drivers
    • 4.1.1 Increasing Cancer Incidences
    • 4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
    • 4.1.3 Growing Geriatric Population
    • 4.1.4 High Healthcare Spending in Developed Economies
    • 4.1.5 Strong Pipeline
    • 4.1.6 Increasing Efficacy in a Wide Variety of Indications
    • 4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
  • 4.2 Challenges
    • 4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments
    • 4.2.2 Sky-High Development Costs of Cancer Immunotherapies
    • 4.2.3 High Cost of Treatment
    • 4.2.4 Lack of Awareness
  • 4.3 Opportunities
    • 4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
    • 4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
    • 4.3.3 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immune Checkpoint Inhibitors Market Outlook 2022

6. Global Immune Checkpoint Inhibitors Sales, by Product Class

  • 6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
    • 6.1.1 Yervoy (Ipilimumab)
  • 6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
    • 6.2.1 Tecentriq (Atezolizumab)
    • 6.2.2 Bavencio (Avelumab)
    • 6.2.3 Imfinzi (Durvalumab)
    • 6.2.4 Opdivo (Nivolumab)
    • 6.2.5 Keytruda (Pembrolizumab)

7. Application of Immune Checkpoint Inhibitors in Major Indications

  • 7.1 Head & Neck Cancer
  • 7.2 Lung Cancer
  • 7.3 Melanoma
  • 7.4 Lymphoma
  • 7.5 Leukemia
  • 7.6 Others

8. Trends & Developments

  • 8.1 Lucrative Investment Trend
  • 8.2 Emergence of Targeted and Combination Therapies
  • 8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
  • 8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

9. Strategic Collaborations & Alliances in the Immune Checkpoint Inhibitors Market

10. Pipeline Analysis of Immune Checkpoint Inhibitors

11. Key Players Analysis

  • 11.1 Genentech, Inc. (A Member of the Roche Group)
  • 11.2 CureTech Ltd.
  • 11.3 NewLink Genetics Corporation
  • 11.4 Novartis AG
  • 11.5 Bristol-Myers Squibb
  • 11.6 Merck & Co., Inc.
  • 11.7 AstraZeneca Plc
  • 11.8 Pfizer Inc
  • 11.9 Ono Pharmaceutical Co., Ltd.
  • 11.10 EMD Serono, Inc.

List of Figures

  • Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
  • Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
  • Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
  • Figure 4-4: Expected Combination Regimen Launches in Oncology
  • Figure 5-1: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
  • Figure 6-1: Global - Yervoy Market (Million US$), 2012-2018
  • Figure 6-2: Global - Tecentriq Market (Million US$), 2016 & 2017
  • Figure 6-3: Global - Bavencio Market (Million US$), 2017-2021
  • Figure 6-4: Global - Imfinzi Market (Million US$), 2017
  • Figure 6-5: Global - Opdivo Market (Million US$), 2014-2016
  • Figure 6-6: Global - Keytruda Market (Million US$), 2014-2016
  • Figure 7-1: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-2: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-3: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-4: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-5: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-6: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-7: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-8: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-9: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-10: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 7-11: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
  • Figure 7-12: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
  • Figure 8-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
  • Figure 8-2: Major Investors in Immuno-Oncology Market (2015-2016)
  • Figure 8-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
  • Figure 10-1: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Product Type (%), 2016
  • Figure 10-2: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Phase (%), 2016
  • Figure 11-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
  • Figure 11-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
  • Figure 11-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
  • Figure 11-4: Novartis AG - Breakup of Sales by Business Segment (%), 2016
  • Figure 11-5: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
  • Figure 11-6: Novartis AG - Breakup of Sales by Geography (%), 2016
  • Figure 11-7: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
  • Figure 11-8: Bristol Myers Squibb - Revenue by Geography (%), 2016
  • Figure 11-9: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
  • Figure 11-10: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
  • Figure 11-11: Merck & Co., Inc. - Revenue by Geography (%), 2016
  • Figure 11-12: AstraZeneca Plc - Revenue by Business Segments (%), 2016
  • Figure 11-13: AstraZeneca Plc - Revenue by Geography (%), 2016
  • Figure 11-14: Pfizer Inc - Revenue by Business Segments (%), 2016
  • Figure 11-15: Pfizer Inc - Revenue by Geography (%), 2016

List of Tables

  • Table 4-1: Immune Checkpoint Inhibitors - Late Stage Research Pipeline
  • Table 6-1: Ongoing Trials for Yervoy
  • Table 6-2: Ongoing Trials for Opdivo
  • Table 6-3: Ongoing Trials for Keytruda
  • Table 7-1: Global - Oncology Incidence by Geography ('000), 2015 & 2020
  • Table 8-1: Selected Immuno-Oncology and Targeted Therapy Combinations
  • Table 9-1: Strategic Collaborations in the Immune Checkpoint Inhibitors Market
  • Table 10-1: Active Immune Checkpoint Inhibitors Programs
  • Table 10-2: Global - Immune Checkpoint Inhibitors Product Pipeline
  • Table 11-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
  • Table 11-2: Genentech, Inc. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-3: Genentech, Inc. - Product Pipeline
  • Table 11-4: CureTech Ltd. - Product Pipeline
  • Table 11-5: NewLink Genetics Corporation- Key Financials (Million US$), 2014-2016
  • Table 11-6: NewLink Genetics Corporation - Product Pipeline
  • Table 11-7: Novartis AG - Key Financials (Billion US$), 2014-2016
  • Table 11-8: Novartis AG - Product Pipeline
  • Table 11-9: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
  • Table 11-10: Bristol Myers Squibb - Commercialized Immune Checkpoint Inhibitors
  • Table 11-11: Bristol Myers Squibb - Product Pipeline
  • Table 11-12: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
  • Table 11-13: Merck & Co., Inc. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-14: Merck & Co., Inc. - Product Pipeline
  • Table 11-15: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
  • Table 11-16: AstraZeneca Plc - Commercialized Immune Checkpoint Inhibitors
  • Table 11-17: AstraZeneca Plc - Product Pipeline
  • Table 11-18: Pfizer Inc - Key Financials (Billion US$), 2014-2016
  • Table 11-19: Pfizer Inc - Commercialized Immune Checkpoint Inhibitors
  • Table 11-20: Pfizer Inc - Product Pipeline
  • Table 11-21: Ono Pharmaceutical Co., Ltd. - Key Financials (Million US$), FY2014-FY2016
  • Table 11-22: Ono Pharmaceutical Co., Ltd. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-23: Ono Pharmaceutical Co., Ltd. - Product Pipeline
  • Table 11-24: EMD Serono, Inc. - Commercialized Immune Checkpoint Inhibitors
  • Table 11-25: EMD Serono, Inc. - Product Pipeline